Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723432 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1HCAR2ALDH1A1 | |
| SCHEMBL1801877 | 0.81 | HCAR2 (0.60) | SMN1; SMN2RAB9ANPC1HCAR2HTT | |
| SCHEMBL12018827 | 0.81 | HCAR2 (0.60) | SMN1; SMN2RAB9ANPC1HCAR2HTT | |
| SCHEMBL3089611 | 0.81 | HCAR2 (0.60) | SMN1; SMN2RAB9ANPC1HCAR2HTT | |
| SCHEMBL31736350 | 0.79 | HCAR2 (0.58) | SMN1; SMN2RAB9ANPC1HCAR2HPGD | |
| SCHEMBL152682 | 0.79 | — | — | |
| SCHEMBL10551080 | 0.79 | — | — | |
| SCHEMBL11173216 | 0.77 | — | — | |
| 2-Thiophenenecarboxaldehyde SCHEMBL6381510 | 0.77 | — | — | |
| SCHEMBL127509 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117835718-A | White light organic electroluminescent composition and application thereof | 深圳大学 | 2024-04-05 | — | — | CN | claimed |
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-4092306-A | Oxidation of hydrazones to the corresponding diazo compounds in the presence of a phase transfer and an oxidation catalyst which is iodine, an iodide or an iodonium salt | GLAXO LABORATORIES LIMITED (EN) | 1978-05-30 | — | — | US | claimed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| CN-117835718-A | White light organic electroluminescent composition and application thereof | 深圳大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-3815689-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | National University Corporation Hokkaido University (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-1028113-A1 | FUSED BENZENE HETEROCYCLE DERIVATIVES AND UTILIZATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-4415566-A | ANTIBIOTICS; BACTERIOSTATS; BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4092306-A | Oxidation of hydrazones to the corresponding diazo compounds in the presence of a phase transfer and an oxidation catalyst which is iodine, an iodide or an iodonium salt | GLAXO LABORATORIES LIMITED (EN) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | SMN1; SMN2 2811/4885RAB9A 3829/4885NPC1 1486/4885 |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | SMN1; SMN2 4304/4885RAB9A 3863/4885NPC1 3250/4885 |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | SMN1; SMN2 2273/4885RAB9A 4312/4885NPC1 4103/4885 |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CDK7, CCNA1, CCR10 | SMN1; SMN2 2820/4885RAB9A 4008/4885NPC1 2071/4885 |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CCNA1, CDK7, CCR10 | SMN1; SMN2 2785/4885RAB9A 3990/4885NPC1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.